Group items tagged

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015', provides an overview of the Respiratory Syncytial Virus (RSV) Infections's therapeutic pipeline.

Prospective partners with the most attractive projects are expected to enhance and expand business potential and scope for uterine cancer therapy globally. Marketers are developing and designing in-licensing and out-licensing strategies based on the identification of emerging players with potentially strong product portfolio. They are also designing effective counter-strategies to gain competitive advantage.

An in-depth analysis of the diverse types of therapeutics under development for T-Cell Lymphomas and identification of emerging players with potentially strong product portfolio assists marketers design effective counter-strategies to gain competitive advantage. Latest updates provide insights into the most attractive projects with emerging opportunities to enhance and expand business potential and scope.

Global Markets Directs, Dengue - Pipeline Review, H1 2014, provides an overview of the Dengues therapeutic pipeline. It also enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Elemental information and data relating to the clinical trials on fatty liver disease including an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe offers a perspective on the fatty liver disease clinical trial scenario. Disease clinical trials by their phase, trial status, prominence of the sponsors pertaining to the number of trials for the key drugs for treating fatty liver disease hints at the dynamics of a particular indication in a condensed manner in addition to the commercial landscape of the major universities, institutes, hospitals or companies.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company.

This report includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Abdominal Obesity.

Interesting info. What other meds can be taken?

As far as I know, Xenical (Orlistat) promotes weight loss by decreasing the amount of dietary fat absorbed in your intestines. You can find out more about it on the Canada Drugs site https://www.canadadrugsdirect.com/. It has to be noted, that this medication should only be used under the supervision of a trained healthcare professional.

Emerging players with potentially strong product portfolio is expected to capture the global Xerosis treatment market. It is essential for the marketers to design effective counter-strategies to gain competitive advantage. A promising pipeline indicates mergers and acquisitions. Devising corrective measures for pipeline projects would also require an in-depth understanding of the Xerosis pipeline depth and focus of indication therapeutics.

This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.